+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Urothelial Cancer Treatment Market 2019-2025

  • PDF Icon


  • June 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5129893
Global Urothelial Cancer Treatment Market Size, Share & Trends Analysis Report, by Therapy (Chemotherapy, Immunotherapy, Others) and Forecast Period 2019-2025.

The global urothelial cancer treatment market is estimated to grow at a CAGR during the forecast period. The rising frequency of urothelial cancer among middle-aged people is driving the market. Urothelial cancer mostly affects older people, 90% of the urothelial cancer patients are older than 55 years and the average age of people are diagnosed with urothelial cancer is 73 years. Moreover, some crucial factors attributing to the positive growth of the market, that are economic growth, public & government awareness.

The global urothelial cancer treatment market is segmented based on the therapy type that includes chemotherapy, immunotherapy, and others. The chemotherapy segment held a significant share in the therapy segment in 2018. Geographically, the market is segmented on the basis of the region that includes North America, Europe, Asia-Pacific, and the rest of the world. North America is expected to have considerable share owing to the availability of drugs, innovations & pipelines, rising cases of urothelial cancer due to the growing geriatric population and growing public awareness.

The major players providing urothelial cancer treatment include Merck & Co. Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Pfizer Inc., Novartis AG, GlaxoSmithKline PLC, Sanofi SA, Eisai Co. Ltd. The strategies adopted by the market players include joint venture and product launches, to increase their competitiveness across a global scale. For instance, in February 2017, Bristol-Myers Squibb’s Opdivo got FDA approval, this drug is used for urothelial cancer treatment. It is an intravenous injection, it can be used for the patients with locally advanced or metastatic urothelial carcinoma.

Research Methodology

The market study of the global urothelial cancer treatment market is incorporated by extensive primary and secondary research conducted by a research team. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include:
  • Reports of companies involved in the market
  • Authentic Public Databases
  • Whitepapers such as research papers and news blogs
  • Company websites and their product catalog
The report is intended for providers, suppliers, and distributors of fiberglass, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and will serve as a source for 360-degree analysis of the market.

The Report Covers:
  • Comprehensive research methodology of the global urothelial cancer treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Insights about market determinants which are stimulating the global urothelial cancer treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusions
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. AstraZeneca PLC Overview Financial Analysis SWOT Analysis Recent Developments
3.3.2. Bristol-Myers Squibb Co. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.3. F. Hoffmann-La Roche AG Overview Financial Analysis SWOT Analysis Recent Developments
3.3.4. Merck & Co. Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.5. Pfizer, Inc. Overview Financial Analysis SWOT Analysis Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Urothelial Cancer Treatment Market by Therapy
5.1.1. Chemotherapy
5.1.2. Immunotherapy
5.1.3. Others( Targeted Therapy & Radiation Therapy)
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Adaptimmune Therapeutics Plc
7.2. Alligator Bioscience AB
7.3. Amgen, Inc.
7.4. AndroScience Corp.
7.5. AstraZeneca PLC
7.6. Bristol-Myers Squibb Co.
7.7. Eisai Co. Ltd.
7.8. Eli Lilly and Co.
7.9. F. Hoffmann-La Roche AG
7.10. GlaxoSmithKline PLC
7.11. Johnson & Johnson Service, Inc.
7.12. Merck & Co, Inc.
7.13. Novartis AG
7.14. Pfizer, Inc.
7.15. Sanofi S.A.
7.16. Sun Pharmaceutical Industries, Ltd.
7.17. Teva Pharmaceutical Industries, Ltd.
7.18. Vault Pharma, Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Adaptimmune Therapeutics Plc
  • Alligator Bioscience AB
  • Amgen, Inc.
  • AndroScience Corp.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson Service, Inc.
  • Merck & Co, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries, Ltd.
  • Teva Pharmaceutical Industries, Ltd.
  • Vault Pharma, Inc.